Journal
CELL REPORTS
Volume 35, Issue 1, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.108959
Keywords
-
Categories
Funding
- Mark Foundation [19-011-MIA]
- Dean's Innovation Fund
- NIAID [5R01AI140539, 1R01AI1502461, R01AI152362]
- NCATS
- Mercatus
- Bill and Melinda Gates Foundation
- Burroughs Wellcome Fund
- NIH
- BWF
Ask authors/readers for more resources
There is an urgent need for antiviral drugs to treat SARS-CoV-2, and screening has identified several potential candidates with different mechanisms of action in lung epithelial cells. Some of these drugs could be used for the treatment of respiratory cells in patients.
There is an urgent need for antivirals to treat the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To identify new candidates, we screen a repurposing library of similar to 3,000 drugs. Screening in Vero cells finds few antivirals, while screening in human Huh7.5 cells validates 23 diverse antiviral drugs. Extending our studies to lung epithelial cells, we find that there are major differences in drug sensitivity and entry pathways used by SARS-CoV-2 in these cells. Entry in lung epithelial Calu-3 cells is pH independent and requires TMPRSS2, while entry in Vero and Huh7.5 cells requires low pH and triggering by acid-dependent endosomal proteases. Moreover, we find nine drugs are antiviral in respiratory cells, seven of which have been used in humans, and three are US Food and Drug Administration (FDA) approved, including cyclosporine. We find that the antiviral activity of cyclosporine is targeting Cyclophilin rather than calcineurin, revealing essential host targets that have the potential for rapid clinical implementation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available